Skip to main content
. 2015 Jun 23;6(27):23671–23687. doi: 10.18632/oncotarget.4409

Figure 2. Modified heparin derivatives inhibit galectin-3-mediated cancer cell adhesion to endothelial cells.

Figure 2

The presence of compounds E (panel A), F (panel C) and G (panel E) and ultra-low molecular weight fractions E3 (panel B), F3 (panel D) and G3 (panel F) each prevented galectin-3-mediated adhesion of ACA19+ cells to a HUVEC monolayer compared with BSA treated control. ***p < 0.001, **p < 0.01, *p < 0.05 by one-way ANOVA, three independent experiments each in triplicate.